Pacer Advisors Inc. Lowers Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Pacer Advisors Inc. reduced its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 503,013 shares of the specialty pharmaceutical company’s stock after selling 144,071 shares during the quarter. Pacer Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $95,095,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vestal Point Capital LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Franklin Resources Inc. increased its stake in Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after buying an additional 1,129,995 shares during the period. Bank of New York Mellon Corp lifted its holdings in Jazz Pharmaceuticals by 160.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock worth $197,516,000 after buying an additional 715,361 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Jazz Pharmaceuticals by 258.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after buying an additional 395,000 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its position in Jazz Pharmaceuticals by 592.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after buying an additional 373,383 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the sale, the director directly owned 9,680 shares of the company’s stock, valued at $2,231,724. The trade was a 10.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 13,098 shares of company stock worth $3,131,906 over the last three months. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $252.86 on Monday. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $261.30. The company’s 50 day moving average is $239.26 and its two-hundred day moving average is $206.67. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The company has a market cap of $15.88 billion, a PE ratio of -12,636.68, a P/E/G ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities analysts predict that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the subject of several research reports. Morgan Stanley restated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Raymond James Financial reiterated an “outperform” rating and issued a $239.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, May 22nd. Finally, Bank of America upped their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.